JR
RVNC

Josh Resnick’s Revance Therapeutics, Inc. RVNC Stock Holding History

Josh Resnick’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,438,669
Closed -$46.3M – 33
2023
Q1 		$46.3M Buy
1,438,669
+503,000
+54% +$15.7M 1.92% 20
2022
Q4 		$17.3M Buy
935,669
+221,669
+31% +$5.07M 1.28% 20
2022
Q3 		$19.3M Buy
+714,000
New +$14.5M 1.22% 19

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $59.5B AUM 35.96% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Josh Resnick's RVNC Position: Q2 2023 in Review

Josh Resnick sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2023, closing a stake of 1,438,669 shares — an estimated $46.3M sold.

Josh Resnick first reported a position in RVNC in Q3 2022 and held it in 3 quarters. The position peaked at $46.3M in Q1 2023. 215 funds tracked by Wall St. Rank hold RVNC as of Q2 2023.

  • Josh Resnick reported no remaining Revance Therapeutics, Inc. position as of Q2 2023 after selling out during the quarter.
  • Josh Resnick sold 1,438,669 Revance Therapeutics, Inc. shares in Q2 2023, an estimated $46.3M.
  • Josh Resnick first reported a position in Revance Therapeutics, Inc. in Q3 2022 and held it in 3 quarters.
  • Josh Resnick's Revance Therapeutics, Inc. position peaked at $46.3M in Q1 2023.
  • 215 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2023.

Based on Jericho Capital Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.